After the intervention of LGS, the aforementioned indicators were reversed, which confirmed the effectiveness of LGS for ALD via attenuating liver steatosis and injury (decreased AST, ALT, TC, TG and HDL-C, increased LDL-C, and alleviated histopathological scores in liver), relieving inflammation (decreased TNF-α, IL-6, and IL-1β) and enhancing alcohol metabolism (increased ADH and ALDH, and reduced CYP2E1 activity). The gene discussed is AVP; the disease is Hepatic steatosis.